PatientsVille.com Logo


Gamma-glutamyltransferase Decreased Medical Research Studies

Up-to-date List of Gamma-glutamyltransferase Decreased Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Gamma-glutamyltransferase Decreased Medical Research Studies

Rank Status Study
1 Recruiting A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia
Condition: Moderate Hypercholesterolemia
Intervention: Dietary Supplement: Probiotics bacterial strains
Outcome Measures: Change of the fasting blood LDL cholesterol concentration;   Change in fasting blood total cholesterol concentration;   Change in fasting blood LDLc concentration;   Change in fasting blood HDLc concentration;   Change in fasting blood ratio total cholesterol / HDLc concentrations;   Change in fasting blood ratio LDLc / HDLc concentrations;   Change in fasting blood triglycerides concentration;   Change in fasting blood Apo A1 concentration;   Change in fasting blood Apo B100 concentration;   Change in fasting blood insulin concentration;   Change in fasting blood glucose concentration;   Change in fasting blood acetate concentration;   Change in fasting blood propionate concentration;   Change in fasting blood acetate / propionate concentrations;   Change in SCORE - European Low Risk Chart of fatal cardiovascular disease;   Change in fasting blood hsCRP concentration;   Complete blood count;   Blood Alkaline Phosphatase;   Blood Alanine Amino Transferase;   Blood Aspartate Amino Transferase;   Blood Gamma Glutamyl Transpeptidase;   Blood total bilirubin;   Blood urea;   Blood creatinine;   Heart rate;   Systolic Blood Pressure;   Diastolic Blood Pressure;   Body weight;   Physical Activity Score;   Total energy intake;   Percentage of energy intake from fat;   Dietary fiber intake;   Saturated Fatty Acids intake
2 Recruiting Zonisamide for Heavy Drinkers With Bipolar Disorder
Conditions: Alcohol Use Disorders;   Bipolar Disorder
Interventions: Drug: Zonisamide;   Drug: Placebo
Outcome Measures: Percentage of total Heavy Drinking Days;   Change on Hamilton Depression Rating Scale;   Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores;   Percentage of Abstinent Days;   Change in Alcohol Urge Questionnaire Score;   Change in Gamma glutamyl transferase (GGT);   Change in Beck Depression Inventory (BDI) Scores;   Percentage of total drinking days;   Change in number of heavy drinking days per week by time;   Change in number of drinks per week by time
3 Unknown  Treatment of Alcohol Dependence and Comorbid Bipolar Disorder
Conditions: Alcohol Dependence;   Bipolar Disorder;   Depression;   Mania;   Psychosis
Interventions: Drug: Lamotrigine;   Drug: Placebo
Outcome Measures: Percent days of abstinence from alcohol;   Drinks per week, drinking days per week, heavy drinking days per week;   Biomarkers of alcohol use: carbohydrate-deficient transferrin, gamma-glutamyltransferase;   Depression as assessed by scores on the Montgomery-Asberg Depression Rating Scale;   Mania/hypomania symptoms as assessed by the Young Mania Rating Scale;   Neurocognitive performance (California Verbal Learning Test, Rey-Osterrieth Complex Figure Test, etc.)
4 Recruiting Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
Condition: Alcohol Dependence
Intervention: Drug: nalmefene
Outcome Measures: Change from baseline in the number of heavy drinking days per month (HDDs) (days/month);   Change from baseline in the number of HDDs per week (days/week);   Change from baseline in total alcohol consumption (TAC) (g alcohol/day);   Change from baseline in TAC (g alcohol/day);   Response Shift Drinking Risk Level (RSDRL);   Response Low Drinking Risk Level (RLDRL);   Response defined as ≥70% reduction in TAC;   Response defined as 0 to 4 HDDs (days/month);   Clinical Global Impression, global improvement (CGI-I).;   Change from baseline in Clinical Global Impression, Severity of illness (CGI-S);   Change in the Short-Form 36-Item Health Survey (SF-36);   Change in liver stiffness;   Category shift in fibrosis stage;   Change in transaminases and γ-glutamyl transferase (γGT);   Change in bilirubin, albumin, and International Normalized Ratio (INR);   Number of adverse events
5 Unknown  Indocyanine Clearance Rate and Septic Liver Injury
Condition: Sepsis
Outcome Measures: Plasma clearance of indocyanine green;   Transaminase;   Bilirubin;   Prothrombin time;   Lactate;   γ-glutamyl transpeptidase;   Cholinesterase
6 Unknown  Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
Condition: Cholestasis
Intervention: Drug: tauroursodeoxycholic acid
Outcome Measure:
7 Recruiting A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Biological: IMM-124E;   Other: Placebo
Outcome Measures: Body Temperature;   Percentage Fat Content of the Liver;   Adverse Events;   Respiratory Rate;   Pulse Rate;   Systolic Blood Pressure;   Diastolic Blood Pressure;   Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis;   Serum Alanine Aminotransaminase (ALT);   Peak serum concentration (Cmax);   Minimum serum concentration (Cmin);   Area Under the Concentration Time Curve (AUC);   Elimination Half Life (T1/2);   Body Mass Index (BMI);   Waist Circumference;   Waist:Hip Ratio;   Hemoglobin (HB)A1C;   Homeostatic Model Assessment of Insulin Resistance (HOMA-IR);   Total Cholesterol;   Triglycerides;   Low density lipoprotein (LDL);   High Density Lipoprotein (HDL);   Serum Aspartate Aminotransaminase (AST);   Bilirubin;   Albumin;   Gamma Glutamyl Transpeptidase (GGT)
8 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
Outcome Measures: Changes from baseline in liver iron concentration (LIC) and heart iron concentration (HIC) determined by Magnetic Resonance Imaging (MRI), and in bone marrow iron content determined by microscopy after treatment with deferasirox.;   Change of hepcidin concentration in serum;   Change of non-transferrin bound iron (NTBI) concentration in serum;   Change of multiple trace metals in serum;   Change of intracellular signal molecules, mTOR, NFkB and stress sensor p53 in blood cells;   Change of 8-oxodG in urine;   Change of Cu,Zn-SOD activity in erythrocyte hemolysate;   Clinical chemistry: Na, K, Ca, Creatinine, creatinine kinase, CRP, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GT), lactate dehydrogenase (LD), albumin, bilirubin.;   Urine routine test strip for detection of blood, protein, and nitrite;   Ferritin concentration in serum;   Transferrin saturation in serum;   HbA1c;   INR ( International normalized ratio);   Analysis of hemoglobin, reticulocytes, hematocrit, MCV, leukocyte count (total and differential), and platelets;   Urine trace metals;   Bone marrow sample
9 Recruiting Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: ursodeoxycholic acid (UDCA)
Outcome Measures: The primary outcome will be the change in alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) or biomarkers for inflammation in study subjects at baseline compared to the end of Phase III (UDCA discontinuation) of the study.;   A secondary outcome will be the change in ALT, GGT or biomarkers for inflammation in study subjects at the end of Phase III (UDCA discontinuation) compared to the end of Phase IV (UDCA reinstitution) of the study.
10 Recruiting Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
Interventions: Behavioral: Mediterranean lifestyle;   Behavioral: Mediterranean Diet
Outcome Measures: Serum levels of alanine aminotransferase (ALT);   Serum levels of alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT);   Liver stiffness;   Histological disease activity;   Inflammatory and oxidative stress markers

These studies may lead to new treatments and are adding insight into Gamma-glutamyltransferase Decreased etiology and treatment.

A major focus of Gamma-glutamyltransferase Decreased research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Gamma-glutamyltransferase Decreased